Real-World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study

Overview

Journal Haemophilia

Specialty Hematology

Date 2024 Dec 18

PMID 39692331

Authors

Yoshiyuki Ogawa

Kagehiro Amano

Yoshimasa Sugao

Daisuke Nosaka

Yoichi Murakami

Hiroki Adachi

Keiji Nogami

Affiliations

Soon will be listed here.

Abstract

Introduction: Acquired haemophilia A (AHA) is characterized by the development of autoantibodies against factor VIII, reducing its activity and potentially resulting in bleeding.

Aim: To assess the characteristics of people with AHA undergoing rehabilitation and/or with low activities of daily living (ADL) scores, thereby characterizing unmet needs in the management of AHA and informing treatment optimization.

Methods: ORIHIME II, the largest epidemiological and treatment survey of AHA in Japan, is a descriptive, retrospective, observational study conducted using health claims data from April 2008 to October 2021. The primary outcome measures were rehabilitation practice and ADL scores on hospital admission and discharge; use of haemostatic agents and immunosuppressive therapy were also assessed.

Results: Overall, 427 patients in Japan were eligible for the study. Median (Q1-Q3) age was 78.0 (70.0-84.0) years; 264 patients (61.8%) were male. Median (Q1-Q3) time to start rehabilitation was 9 (4-21) and 14 (6-31) days for those with an admission ADL score of <85 and ≥85, respectively. Of the 427 patients, 249 underwent rehabilitation. The most common rehabilitation type was for disuse syndrome; haemostatic agents were more commonly used in patients undergoing earlier rehabilitation.

Conclusion: The physical condition of the patient at hospitalization was associated with rehabilitation practice and the ability of the patient to perform day-to-day activities independently. Treatment strategies should be optimized to allow initiation of rehabilitation as early as possible in the course of AHA.

References

Mlinac M, Feng M . Assessment of Activities of Daily Living, Self-Care, and Independence. Arch Clin Neuropsychol. 2016; 31(6):506-16. DOI: 10.1093/arclin/acw049. View

Granger C, Albrecht G, Hamilton B . Outcome of comprehensive medical rehabilitation: measurement by PULSES profile and the Barthel Index. Arch Phys Med Rehabil. 1979; 60(4):145-54. View

Granger C, Hamilton B, GRESHAM G, KRAMER A . The stroke rehabilitation outcome study: Part II. Relative merits of the total Barthel index score and a four-item subscore in predicting patient outcomes. Arch Phys Med Rehabil. 1989; 70(2):100-3. View

Yousphi A, Bakhtiar A, Cheema M, Nasim S, Ullah W . Acquired Hemophilia A: A Rare but Potentially Fatal Bleeding Disorder. Cureus. 2019; 11(8):e5442. PMC: 6797011. DOI: 10.7759/cureus.5442. View

Knoebl P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L . Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10(4):622-31. DOI: 10.1111/j.1538-7836.2012.04654.x. View

Pishko A, Doshi B . Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice. J Blood Med. 2022; 13:255-265. PMC: 9112043. DOI: 10.2147/JBM.S284804. View

Coppola A, Franchini M, Tripodi A, Santoro R, Castaman G, Marino R . Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. Blood Transfus. 2022; 20(3):245-262. PMC: 9068356. DOI: 10.2450/2022.0238-21. View

Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G . Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015; 13(3):498-513. PMC: 4614303. DOI: 10.2450/2015.0141-15. View

Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R . A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023; 21(3):534-545. DOI: 10.1016/j.jtha.2022.10.004. View

10.

Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T . A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012; 18(10):1570-4. DOI: 10.1038/nm.2942. View

11.

Hayashida K, Murakami G, Matsuda S, Fushimi K . History and Profile of Diagnosis Procedure Combination (DPC): Development of a Real Data Collection System for Acute Inpatient Care in Japan. J Epidemiol. 2020; 31(1):1-11. PMC: 7738645. DOI: 10.2188/jea.JE20200288. View

12.

Kosse N, Dutmer A, Dasenbrock L, Bauer J, Lamoth C . Effectiveness and feasibility of early physical rehabilitation programs for geriatric hospitalized patients: a systematic review. BMC Geriatr. 2013; 13:107. PMC: 4016515. DOI: 10.1186/1471-2318-13-107. View

13.

Amano K, Seita I, Higasa S, Sawada A, Kuwahara M, Shima M . Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data. Haemophilia. 2016; 23(1):50-58. DOI: 10.1111/hae.13033. View

14.

Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M . International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7):1791-1801. PMC: 7327664. DOI: 10.3324/haematol.2019.230771. View

15.

Paolucci S, Antonucci G, Grasso M, Morelli D, Troisi E, Coiro P . Early versus delayed inpatient stroke rehabilitation: a matched comparison conducted in Italy. Arch Phys Med Rehabil. 2000; 81(6):695-700. DOI: 10.1016/s0003-9993(00)90095-9. View

16.

Granger C, Dewis L, Peters N, Sherwood C, Barrett J . Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil. 1979; 60(1):14-7. View

17.

Ikeda Y, Kubo T, Oda E, Abe M, Tokita S . Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan. J Diabetes Investig. 2018; 10(3):857-865. PMC: 6497613. DOI: 10.1111/jdi.12959. View

18.

Kruse-Jarres R, Kempton C, Baudo F, Collins P, Knoebl P, Leissinger C . Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017; 92(7):695-705. DOI: 10.1002/ajh.24777. View

19.

Ogawa Y, Amano K, Matsuo-Tezuka Y, Okada N, Murakami Y, Nakamura T . ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database. Int J Hematol. 2022; 117(1):44-55. PMC: 9813148. DOI: 10.1007/s12185-022-03467-w. View

20.

Tiede A, Klamroth R, Scharf R, Trappe R, Holstein K, Huth-Kuhne A . Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2014; 125(7):1091-7. PMC: 4326770. DOI: 10.1182/blood-2014-07-587089. View